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Introduction
Intra-alveolar fibrin deposition is frequently found during acute inflammatory lung diseases 1 . The increased tendency to form fibrin deposits during lung inflammation likely is the result of stimulation of the coagulation system with concurrent inhibition of the fibrinolytic system. Early mediators of fibrinolysis are plasminogen activators (PA), which activate plasminogen into plasmin, a potent protease that degrades fibrin into fibrin degradation products. PA are controlled by specific inhibitors 2 of which PA inhibitor type I (PAI-1) is considered most important, inactivating both urokinase type (uPA) and tissue type (t)PA 3,4 .
The pulmonary compartment is an important site of PAI-1 production and activity.
Indeed, PAI-1 mRNA is induced in tissues of endotoxemic animals, in particular in the lung 5, 6 . In addition, broncho-alveolar lavage fluid (BALF) of patients with interstitial pulmonary fibrosis, sarcoidosis and acute respiratory distress syndrome (ARDS) display elevated levels of PAI-1, which is held responsible for the suppressed alveolar fibrinolytic activity in these patients 7-11 . Recently, elevated PAI-1 concentrations were reported in bronchoalveolar lavage fluid (BALF) of patients with severe pneumonia requiring mechanical ventilation, which coincided with a profoundly suppressed fibrinolytic activity in the alveolar space 11 . BALF PAI-1 levels were unaltered in patients with less severe pneumonia, breathing spontaneously. Together these data indicate that a number of lung diseases are associated with increased PAI-1 levels in the airways, including pneumonia. Knowledge of the role of this endogenous PAI-1 in host defense against respiratory pathogens is highly limited, however. The main objective of this study was to determine the role of endogenous PAI-1 in the innate immune response to bacterial pneumonia. For this, we first investigated to which extent PAI-1 is produced and the fibrinolytic system is active in the infected lung of patients with unilateral community acquired pneumonia (CAP). Furthermore, we evaluated the role of PAI-1 in host defense during pneumonia caused by Streptococcus only.
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Materials and Methods

PATIENT STUDY
Study population 4 patients with a unilateral CAP were enrolled into the study. They fulfilled the following criteria: fever (>37.7ºC), PaO 2 > 7.5 kPa while breathing room air, new unilateral infiltrate on chest roentgenogram within two days after admission and no antibiotic pre-treatment. Patients were excluded when they were hospitalized within two weeks prior to this admission or when they used immunosuppressive drugs. They were three men and one woman (mean age 41±5 yr (mean ± SE). 10 healthy volunteers, not taking any medication (mean age 32±8 yr) served as controls. The protocol was reviewed and approved by the Medical Ethics Committee of the University of Amsterdam and written informed consent was obtained from all subjects.
Broncho-alveolar lavage (BAL) BAL was performed in a standardized fashion according to the guidelines of the American Thoracic Society, using a flexible fiberoptic video-bronchoscope, within 12 h after admission. Seven successive 20 ml aliquots of prewarmed 0.9% saline were instilled in a subsegment of the lung and each aspirated immediately with low suction. BAL was performed at the uninfected side first in a subsegment of the middle lobe or lingula. This was followed by lavaging a subsegment of the infected lobe. Generally, 10-15 ml of each 20 ml aliquot was recovered. The recovery from the infected and uninfected side did not differ. Triton(X-100), Pepstatin A, Leupeptin, Aprotinine (20ng/ml), pH 7.4) and spinned at 1500 x g at 4 0 C for 15 minutes; the supernatant was frozen at -20 0 C until cytokine measurement.
Broncho-alveolar lavage
The trachea was exposed through a midline incision and cannulated with a sterile 22-gauge Abbocath-T catheter (Abbott, Sligo, Ireland). BAL was performed by instilling two 0.5 ml aliquots of sterile saline. 0.9-1 ml of lavage fluid was retrieved per mouse, and total cell numbers were counted from each sample in a only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From hemacytometer (Emergo, Amsterdam, the Netherlands). BALF differential cell counts were determined on cytospin preparations stained with modified Giemsa stain (DiffQuick; Baxter, McGraw Park, Ill). Assays Murine PAI-1 antigen levels in lung homogenates were measured by ELISA, calibrated with recombinant murine PAI-1 as described 36 . For this purpose, the antimurine PAI-1 monoclonal antibody H34G6 (4 µg/ml) was coated on microtiter plates for 48 h at 4°C. Bound PAI-1 in the samples was revealed using a biotinylated and diluted (1:250) rabbit polyclonal antiserum raised against murine PAI-1, incubated for 1 h at 37°C, and then by a peroxidase-labeled avidin-biotin complex. Cytokine levels were measured using commercially available ELISAs, in accordance with the manufacturers recommendations: Tumor necrosis factor (TNF), Interleukin 6 (IL-6) (Pharmingen, San only.
Histologic examination
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Diego, CA), Interleukin 1 (IL-1 ). Detection limits were 50 pg/ml (TNF), 37pg/ml (IL-6), 150 pg/ml (IL-1 ). MPO activity was measured as described previously 37 . Briefly, lung tissue was homogenized in potassium phosphate buffer, pH7.4. After centrifugation Comparisons between groups were conducted using the Mann Whitney U test. Survival curves were compared by log-rank test. P < 0.05 was considered to represent a statistically significant difference.
Results
Alveolar fibrinolysis in pneumonia patients
Patient characteristics are presented in table I. All patients recovered uneventfully with antibiotic therapy. All patients underwent bilateral BAL within 12 h after admission, first at the uninfected side and then in the area with the infiltrate on the chest X-ray, and fibrinolytic mediators were measured in BALF. BALF from healthy subjects served as control (Figure 1 ). PAI-1 antigen levels were increased in BALF of infected lungs compared with PAI-1 levels in BALF from uninfected lungs and healthy controls. In
addition, PAI-1 antigen concentrations were higher in BALF from uninfected lungs of CAP patients than in BALF from healthy controls. Elevated PAI-1 levels were associated with a reduced broncho-alveolar PA activity, which was reduced in infected lungs of patients compared to uninfected lungs and healthy individuals. uPA and tPA antigen levels, however, were increased in BALF of infected lungs compared to uninfected BALF. This discrepancy might be explained by the fact that the uPA and tPA antigen assays detect free PA's as well as PA's in complex with their inhibitor PAI-1. only.
For 
Production of PAI-1 during murine pneumococcal pneumonia
To evaluate the role of PAI-1 in host defense during CAP, we used a pneumococcal pneumonia mouse model and compared host responses in PAI-1 -/-and Wt mice. To confirm PAI-1 production in this model, we measured PAI-1 levels in lung homogenates after induction of pneumonia. Intranasal administration of S. pneumoniae increased the concentrations of PAI-1 in lung homogenates obtained 48h after inoculation (p<0.05 vs. control; Figure 2A) ; mice with pneumonia also showed an increase of plasma PAI-1 antigen compared to control mice (PAI-1 2.8 ± 0.9 ng/ ml in controls; at 48h: 19.8 ± 18.6 ng/ml;p< 0.09).
only.
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To obtain insight into the cellular source of PAI-1 in the normal and infected lung, we performed in situ hybridization. In normal lung, a faint signal for PAI-1 mRNA transcripts was detected in endothelial cells as well as in bronchiolar and alveolar epithelium ( Figure 2B ). At 48h after infection, a strong expression of PAI-1 mRNA was observed predominantly in vessels showing endothelial injury, in inflamed bronchi, in areas of inflammatory infiltrates and areas of pleuritis. 
Inflammatory cell influx in BALF
To obtain insight in the role of PAI-1 in cell migration, we compared leukocyte counts in BALF of PAI-1 -/-and Wt mice 48 h after inoculation with S. pneumoniae. PAI-1 -/-mice had a similar influx of neutrophils in their BALF when compared to Wt mice (Table II) .
In accordance, MPO activity in lung homogenates at 48h after inoculation was similar in both genotypes (Table II) . MPO (U/ml) 3.0 ± 0.9 4.8 ±0.5
Data are mean ± SEM of 6 mice per group, measured 48h after i.n.
inoculation. AM is alveolar macrophages. PMN is polymorphonuclear cells.
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Histopathology
At 24 and 48h after inoculation, the lungs showed patchy and sometimes dense inflammatory infiltrates, which was similar in both groups (Figure 3) . Formation of thrombi was not observed in the blood vessels of either group. 
Bacterial outgrowth
To investigate the potential role of PAI-1 in the clearance of S. pneumoniae from the lungs, we determined the number of bacteria in lungs 24 and 48h after inoculation. At both time points PAI-1 -/-mice had similar numbers of CFU in their lungs as Wt mice ( Figure 4A and B) . Furthermore, blood cultures were positive in 62.5% of mice of both strains at 24 h, and in 90% and 75% of Wt and PAI-1 -/-mice respectively at 48h (non significant). 
Survival
To investigate whether PAI-1 influences mortality, we assessed survival twice daily in Wt and PAI-1 -/-mice after intranasal inoculation with S. pneumoniae up to ten days postinoculation ( Figure 4C) . No difference was found between the two groups.
For
Cytokines
Cytokines play an important role in the regulation of host defense against pneumonia 38 and the PA sytem can influence the production of these mediators 39 . Therefore, we measured the concentrations of TNF, IL-6 and IL-1 in lung homogenates. All cytokine levels measured were similar in PAI-1 -/-and Wt mice (data not shown).
Host response to pneumonia in Plg -/-mice
The studies with PAI-1 -/-mice suggested that PAI-1 does not influence host defense against pneumococcal pneumonia. In addition these experiments did not reveal a role for PAI-1 in the migration of leukocytes to the site of infection. PAI-1 -/-mice display a basal state of enhanced fibrinolytic activity, which is the result of the loss of the important inhibitory function of PAI-1 towards PAs 31,33 . To evaluate whether deficiency to generate plasmin, the active end product of the fibrinolytic system, influences the innate immune response to pneumonia, we next infected Plg -/-and Wt mice with S. pneumoniae.
Similar to PAI-1 -/-mice, Plg -/-mice displayed no difference in leukocyte recruitment into BALF (data not shown) and equal numbers of S. pneumoniae CFU in their lungs at 48h
postinoculation when compared to Wt mice ( Figure 5A ). In addition Plg -/-and Wt mice demonstrated similar mortality rates ( Figure 5B ).
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In earlier investigations, changes in the alveolar hemostatic balance have in particular been studied in patients with ARDS 11, 42, 43 . In these patients elevated PAI-1 concentrations have been documented in BALF, together with a profoundly decreased fibrinolytic activity. Recently, similar changes were reported in patients with severe pneumonia requiring mechanical ventilation 11 . Patients with less severe pneumonia, however, who breathed spontaneously, did not display elevated PAI-1 levels in their BALF 11 . These data contrast with our present findings of increased PAI-1 levels and suppressed PA activity at the site of the infection in patients with CAP. It is conceivable that the timing of the BAL procedure contributed to this discrepancy, i.e. in the earlier investigation BAL was performed following a strictly time-matched protocol, whereas in our study BAL was conducted within 12 h after admission. In addition we lavaged the segment that showed infiltrative changes on the chest X-ray, whereas in the earlier study the lung with " the predominant infection" was examined 11 . Although our study involved only 4 patients, overlap with data obtained from the uninfected site or from healthy lungs did not occur. Thus, our human data, together with the demonstration of PAI-1 mRNA in mouse lungs during pneumococcal pneumonia strongly indicate that PAI-1 is produced locally in the lung during lower respiratory tract infection. PAI-1 has been found to be important for tumor cell invasion and also serves a role as a prognostic marker in septic patients. To our knowledge this study is the first to
show that alveolar PAI-1 levels are increased in BALF obtained from the infected site in unilateral CAP and that this results in a diminished PA activity at the same site. However, mice deficient for PAI-1 or Plg have an unaltered inflammatory cell migration and host defense during pneumococcal pneumonia. Functional studies of the potential role of PAI-1 or other mediators of the fibrinolytic system in pneumonia in humans are lacking, and therefore our data obtained in mice need to be interpreted with caution. With this reservation in mind, current murine data suggest that the fibrinolytic system seems not important for host defense against respiratory tract infection, with an exception for uPA and uPAR, of which their function likely is not related to their role in fibrinolysis, but to their involvement in inflammatory cell migration.
